These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 6721515)
41. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Newby JC; Johnston SR; Smith IE; Dowsett M Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855 [TBL] [Abstract][Full Text] [Related]
42. Adjuvant hormonal therapy for premenopausal women with breast cancer. Brown RJ; Davidson NE Semin Oncol; 2006 Dec; 33(6):657-63. PubMed ID: 17145345 [TBL] [Abstract][Full Text] [Related]
43. Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition. Spicer J; Ellis P Cancer Lett; 2007 Apr; 248(2):165-74. PubMed ID: 16919870 [TBL] [Abstract][Full Text] [Related]
44. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. Rydén L; Jirström K; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Thorstenson S; Jönsson PE; Landberg G J Clin Oncol; 2005 Jul; 23(21):4695-704. PubMed ID: 16034044 [TBL] [Abstract][Full Text] [Related]
45. [What can be now expected of the determination of estrogen and progesterone receptors in the treatment of breast cancers]. Goussard J; Génot JY Bull Cancer; 1994 Jan; 81(1):22-8. PubMed ID: 7949580 [TBL] [Abstract][Full Text] [Related]
46. Identification of endocrine responsive breast and endometrial carcinoma using steroid hormone receptors. Wittliff JL; Day TG; Dean WL; Allegra JC Prog Clin Biol Res; 1988; 276():11-41. PubMed ID: 3051018 [No Abstract] [Full Text] [Related]
47. Estrogen and progesterone receptors in relation to tissue and plasma estrogens, in predicting hormone dependency in human breast cancer. Drafta D Endocrinologie; 1982; 20(2):143-4. PubMed ID: 7123137 [No Abstract] [Full Text] [Related]
48. [The status of hormone therapy in breast cancer in 2001?]. Boussen H; Bouaouina N; Rahal F; Benna F Tunis Med; 2002 Jul; 80(7):359-64. PubMed ID: 12611343 [TBL] [Abstract][Full Text] [Related]
49. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Pietras RJ; Arboleda J; Reese DM; Wongvipat N; Pegram MD; Ramos L; Gorman CM; Parker MG; Sliwkowski MX; Slamon DJ Oncogene; 1995 Jun; 10(12):2435-46. PubMed ID: 7784095 [TBL] [Abstract][Full Text] [Related]
50. [Progress in the endocrine therapy of breast cancer]. Nomura Y Gan No Rinsho; 1985 May; Suppl():114-5. PubMed ID: 4068230 [No Abstract] [Full Text] [Related]
51. [Steroid hormone receptors in breast cancer]. Moyano C; Puga J; Calaf G; Rojas C Rev Chil Obstet Ginecol; 1984; 49(1):15-25. PubMed ID: 6099905 [No Abstract] [Full Text] [Related]
52. The present status of the adjuvant endocrine treatment. Jonat W; Maass H J Steroid Biochem; 1987; 27(1-3):499-502. PubMed ID: 3320540 [TBL] [Abstract][Full Text] [Related]
53. [The clinical value of hormone receptors in the treatment of breast neoplasms]. Trams G Med Lab (Stuttg); 1979 Nov; 32(11):263-9. PubMed ID: 542183 [TBL] [Abstract][Full Text] [Related]
54. Hormone receptor assessment for endocrine therapy in advanced breast cancer. Report of 28 cases. Chen PZ; Mei ZJ; Yao XY; Meng XQ Chin Med J (Engl); 1983 Oct; 96(10):751-3. PubMed ID: 6426873 [No Abstract] [Full Text] [Related]
55. Proliferation characteristics and receptor concentrations in two gynecological carcinomas serially passaged into female nude mice or castrated males. Vering A; Michel RT; Fortmeyer HP; Stegmüller M Strahlenther Onkol; 1989 Jul; 165(7):498-9. PubMed ID: 2749478 [No Abstract] [Full Text] [Related]
56. [Synergistic action of lentinan (LNT) with endocrine therapy of breast cancer in rats and humans]. Kosaka A; Kuzuoka M; Yamafuji K; Imaizumi A; Hattori Y; Yamashita A Gan To Kagaku Ryoho; 1987 Feb; 14(2):516-22. PubMed ID: 3101609 [TBL] [Abstract][Full Text] [Related]
57. [Results and limits of endocrine therapy of carcinoma of the breast]. Cocconi G Ric Clin Lab; 1985; 15 Suppl 2():73-85. PubMed ID: 3912951 [TBL] [Abstract][Full Text] [Related]
58. [Carcinoma of the breast in the pre- and post-menopausal period]. Sismondi P; Giai M; Zola P; Barengo R; De Fabiani E Minerva Ginecol; 1987 Mar; 39(3):153-61. PubMed ID: 3299152 [No Abstract] [Full Text] [Related]
59. Evaluation of estrogen dependency of human breast cancers. II. Clinical evaluation of tamoxifen in advanced primary and recurrent breast cancer. Nishiki M; Yamane M; Amano K; Yasuda K; Okumichi T; Ezaki H Hiroshima J Med Sci; 1984 Jun; 33(2):163-6. PubMed ID: 6480380 [No Abstract] [Full Text] [Related]
60. [Hormone treatment of breast cancer]. Gröhn P Duodecim; 1991; 107(8):603-10. PubMed ID: 1364913 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]